All In Biotech

Drug Trial Radar · NCT02224157

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,215 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,215

Actual

Start

Nov 28, 2014

Primary completion

Aug 16, 2017

Study completion Aug 16, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort 'as needed' will be compared with Pulmicort (budesonide) Turbuhaler twice daily plus terbutaline Turbuhaler 'as needed'

Conditions

  • Asthma

Interventions

  • budesonide/formoterol 'as needed' + budesonide placebo bidDrug

    Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment

  • budesonode bid + terbutaline 'as needed'Drug

    Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Severe Asthma Exacerbation Rate - Non-inferiority AnalysisTime frame: up to 52 weeks
  2. Annual Severe Asthma Exacerbation Rate - Superiority AnalysisTime frame: up to 52 weeks

Locations

340 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Sydney, Australia

  • Research Site

    Botucatu, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Goiânia, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Sorocaba, Brazil

  • Research Site

    Blagoevgrad, Bulgaria

  • Research Site

    Pernik, Bulgaria

  • Research Site

    Petrich, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Razlog, Bulgaria

  • Research Site

    Sliven, Bulgaria

  • Research Site

    Smolyan, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Stara Zagora, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Vidin, Bulgaria

  • Research Site

    Yambol, Bulgaria

  • Research Site

    Curicó, Chile

  • Research Site

    Quillota, Chile

  • Research Site

    Santiago, Chile

  • Research Site

    Santiago, Chile

Showing 40 of 340 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.